- Receptos (RCPT +22.7%) soars after saying the DMC for its Phase 2/3 trial of RPC1063 in RMS has recommended both the continuation of the Phase 2 portion of the study and the initiation of the Phase 3 component.
- The company says data from an interim analysis "support the RPC1063 differentiation profile and [is] consistent with data from prior RPC1063 studies."
- Expect top-line data from Phase 2 in mid-2014. (PR)
Receptos to move RPC1063 into Phase 3
Dec 5 2013, 10:03 ET